Pomerantz LLP Reminds Investors with Losses on their Investment in Inspire Medical Systems, Inc. – INSP

NEW YORK CITY, NY / ACCESS Newswire / December 22, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. ("Inspire" or the "Company") . Such investors are advised to contact Danielle Peyton at 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Inspire and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.You have until January 5, 2026 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Inspire securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.[Click here for information about joining the class action]On August 4, 2025, Inspire disclosed that the launch of Inspire V, the Company's new sleep apnea device, was facing an "elongated timeframe" due to a number of previously undisclosed headwinds. First, "many centers did not complete the training, contracting and onboarding criteria required prior to the purchase and implant of Inspire V." Inspire also disclosed that, although Inspire V's CPT code had been approved for Medicare patients, "software updates for claims submissions and processing did not take effect until July 1," which meant that "implanting centers would not be able to bill for those procedures until July 1." As a result, many treatment centers simply chose to continue treating with the Inspire IV device until then. Finally, investors also learned for the first time that excess inventory was also negatively impacting the Inspire V rollout. As a result of the foregoing issues, Inspire reduced its earnings guidance by more than 80%, from a range of $2.20 to $2.30 per share to just $0.40 to $0.50 per share.On this news, Inspire's stock price fell $42.04 per share, or more than 32%, to close at $87.91 per share on August 5, 2025.Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.Attorney advertising. Prior results do not guarantee similar outcomes.SOURCE: Pomerantz LLPView the original press release on ACCESS Newswire